Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
Even Moderate Alcohol Use Raises Liver Fibrosis Risk in HIV/HCV Coinfected People
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 06 May 2014 00:00
- Written by University of Pennsylvania
People with HIV alone or hepatitis C virus alone were more likely to have advanced liver fibrosis if they drank more alcohol, but people coinfected with both HIV and HCV had a greater risk of advanced fibrosis even with moderate or "non-hazardous" drinking, according to a report in the May 15 edition of Clinical Infectious Diseases.
Can Coffee Help Prevent Liver Fibrosis?
- Details
- Category: Fibrosis & Cirrhosis
- Published on Friday, 07 February 2014 00:00
- Written by Liz Highleyman
There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.
Coverage of the 2013 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Wednesday, 30 October 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
10/30/13
AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis
- Details
- Category: Fibrosis & Cirrhosis
- Published on Tuesday, 26 November 2013 00:00
- Written by Liz Highleyman
Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.
IAS 2013: FibroScan Predicts Liver Decompensation and Death Among HIV/HCV Coinfected People
- Details
- Category: HCV Disease Progression
- Published on Monday, 08 July 2013 00:00
- Written by Liz Highleyman
The non-invasive transient elastometry method of estimating liver damage may be a better way to predict which people coinfected with HIV and hepatitis C will progress to decompensated liver cirrhosis and death, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).
More Articles...
- EASL 2013: HIV/HCV Coinfected Patients More Likely to Develop Cirrhosis, but Treatment Lowers Risk
- EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
Web Design and Development by